NASDAQ:JANX

Janux Therapeutics Stock Insider Trading

etoro logo Buy JANX
*Your capital is at risk
$13.59
-0.190 (-1.38%)
At Close: Jun 03, 2026

Janux Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 90.43. In total, the insiders bought 3.66M and sold 57.74K JANX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
90.43
Buy 3.66M shares
Sell 57.74K shares
83% Buy Activity
Strong Negative Correlation
Buy Signal High Confidence
Jun 01, 2026

Analysis Breakdown:

  • Strongly supported by a very high Insider Power Score of 90.43.
  • Confidence increased due to high data reliability score of 100.
  • Supported by overwhelming buy-side pressure (83% buys).

Historical Insider Trades

Date Type Person Role Amount
May 14, 2025
Buy
Common Stock
J-Other
Doyle Janeen Noel
Insider
Other 0
Value: $0
May 01, 2025
Buy
Stock Option (right to buy)
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 333
Value: $14.0K
May 01, 2025
Buy
Common Stock
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 333
Value: $14.0K
May 01, 2025
Sell
Common Stock
S-Sale
Meyer Andrew Hollman
Chief Business Officer
Officer 2 933
Value: $93.7K
May 01, 2025
Sell
Common Stock
S-Sale
Meyer Andrew Hollman
Chief Business Officer
Officer 400
Value: $13.0K
May 01, 2025
Sell
Common Stock
S-Sale
Meyer Andrew Hollman
Chief Business Officer
Officer 400
Value: $13.0K
May 01, 2025
Sell
Common Stock
S-Sale
Meyer Andrew Hollman
Chief Business Officer
Officer 2 933
Value: $93.7K
May 01, 2025
Buy
Common Stock
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 333
Value: $14.0K
May 01, 2025
Buy
Stock Option (right to buy)
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 333
Value: $14.0K
Apr 21, 2025
Buy
Stock Option (right to buy)
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $14.0K
Apr 21, 2025
Buy
Common Stock
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $14.0K
Apr 21, 2025
Sell
Common Stock
S-Sale
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $100.0K
Apr 21, 2025
Sell
Common Stock
S-Sale
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $100.0K
Apr 21, 2025
Buy
Common Stock
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $14.0K
Apr 21, 2025
Buy
Stock Option (right to buy)
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $14.0K
Mar 07, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 110 206
Value: $3.42M
Mar 07, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 110 206
Value: $3.42M
Mar 06, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 372 093
Value: $11.5M
Mar 06, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 372 093
Value: $11.5M
Mar 05, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 37 455
Value: $1.17M
Mar 05, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 304 287
Value: $9.30M
Mar 05, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 304 287
Value: $9.30M
Mar 05, 2025
Buy
Common Stock
P-Purchase
Ra Capital Management, L.p.
Director 37 455
Value: $1.17M
Mar 03, 2025
Buy
Stock Option (right to buy)
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $14.0K
Mar 03, 2025
Buy
Common Stock
M-Exempt
Meyer Andrew Hollman
Chief Business Officer
Officer 3 334
Value: $14.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT JANUX THERAPEUTICS, INC.
Janux Therapeutics
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE